[Ip-health] The List of Excluded Middle-Income Countries
mkamalyanni at Oxfam.org.uk
Mon Sep 15 08:05:36 PDT 2014
Am surprised that Yemen is considered middle income country. Last I knew
it was low income.
Does that mean that the license can cover Egypt, Cameroon and Mongolia?
three high burden countries? If so, these countries can get Indian
medicine for US $ 100-400 instead of the price offered by Gilead of the
$900 (Egypt in Mongolia)
Mohga (Dictating to the computer so please forgive silly mistakes)
Dr. Mohga M Kamal-Yanni
Senior health & HIV policy advisor, Oxfam GB
John Smith Drive, Oxford, OX4 2JY, UK
UK Mobile + 44 (0)777 62 55 884
Follow me @MohgaKamalYanni
From: Priti Radhakrishnan <priti at i-mak.org>
To: Ip-health at lists.keionline.org
Date: 15/09/2014 14:20
Subject: [Ip-health] The List of Excluded Middle-Income Countries
Sent by: "Ip-health" <ip-health-bounces at lists.keionline.org>
Here is the list of excluded middle-income countries:
On Mon, Sep 15, 2014 at 8:38 AM, Priti Radhakrishnan <priti at i-mak.org>
> I-MAK has analyzed the cost implications of the licenses announced today
> by Gilead Sciences on the Hepatitis C drug sofosbuvir. The 3 page report
> available here: *http://tinyurl.com/mq35xdl <http://tinyurl.com/mq35xdl
> Gilead is reportedly excluding 51 middle-income countries (MICs) from
> license for sofosbuvir, an oral hepatitis C drug. Across these MICs
> <https://mail.google.com/mail/u/0/#148771184ad8acd4__ftn2>, where nearly
> 50 million people are infected with hepatitis C virus (HCV), lack of
> to generic sofosbuvir will increase the total cost of curing hepatitis C
> an estimated *$60 billion dollars, *according to I-MAK?s analysis.
> I-MAK?s team based this estimate on generic price projections for
> sofosbuvir (~$135-400 per 12-week course of treatment), and the
> that Gilead?s MIC price would be ~75% more than the $900 price they are
> expected to charge to low-income countries.
> <https://mail.google.com/mail/u/0/#148771184ad8acd4__ftn5> Even if
> were to extend its $900 access price to all middle-income countries ?
> is unlikely ? these countries would still need to spend ~$30 billion
> to treat their HCV patients than if generic versions of sofosbuvir were
> available. This underscores the need to address patent barriers for
> sofosbuvir to make HCV treatment affordable for these middle-income
> We emphasize that the middle-income country price we used of $1,567 for
> sofosbuvir (with the 75% price premium) is a low-end estimate, and
> indicate that excluded countries have been quoted a much higher price
> $7,000 for sofosbuvir). Therefore, the $60 billion estimate is likely to
> very conservative indeed.
> Leaving large populations untreated instead of curing them will allow
> epidemic to keep spreading. To meaningfully contribute to the solution,
> Gilead Sciences will need to reduce its price of sofosbuvir and promote
> robust generic competition in the 51 middle-income countries it has
> excluded from the license.
> *Priti Radhakrishnan*
> Co-Founder and Director of Treatment Access, I-MAK
> Echoing Green Fellow | Pop!Tech Fellow | Asia Society Associate Fellow
> *"Where innovation meets access to affordable medicines"*
> *Website: *www.i-mak.org
> *Skype:* pritiwho
> *Mobile:* +1 917 703 2876
> *E-mail:* priti at i-mak.org
Ip-health mailing list
Ip-health at lists.keionline.org
Oxfam works with others to overcome poverty and suffering.
Oxfam GB is a member of Oxfam International and a company limited by guarantee registered in England No. 612172.
Registered office: Oxfam House, John Smith Drive, Cowley, Oxford, OX4 2JY.
A registered charity in England and Wales (no 202918) and Scotland (SC 039042)
More information about the Ip-health